AbbVie Inc. (ABBV)

80.06
NYSE : Health Technology
Prev Close 81.15
Day Low/High 79.87 / 81.10
52 Wk Low/High 75.62 / 104.55
Avg Volume 5.63M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 119.97B
EPS 3.70
P/E Ratio 22.67
Div & Yield 4.28 (4.98%)
Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

AbbVie's Cancer Drug Setback Provides Buying Opportunity

AbbVie's Cancer Drug Setback Provides Buying Opportunity

The biopharma company's shares took a dive on Thursday, March 22, after it said it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small-cell lung cancer.

Jim Cramer: No Place to Go and Fewer Places to Hide

Jim Cramer: No Place to Go and Fewer Places to Hide

Just not a great day.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal Of Marketing Authorizations For ZINBRYTA® (daclizumab) For Relapsing Multiple Sclerosis

Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis.

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Traders should still be long and looking for higher highs. Let's check the charts and indicators again.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Jim Cramer asks: Is every one of these vexing VIX derivatives going to have to go bust before this torture ends? Looks like it.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

AbbVie Becomes #224 Most Shorted S&P 500 Component, Replacing Xylem

AbbVie Becomes #224 Most Shorted S&P 500 Component, Replacing Xylem

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

Don't worry about missing anything, we haven't solved the bond conundrum and the evidence says we get to 3% with selloffs on the way.

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.

Activating My Dip-Buying Shopping List

Activating My Dip-Buying Shopping List

I added to two positions Tuesday, as growth catalysts are in play this earnings season.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

AbbVie Could Climb Even Higher

AbbVie Could Climb Even Higher

AbbVie prices are way above the rising 50-day moving average line.

Jim's Daily Rundown

Jim discusses Honeywell and Abbott Labs earnings as well as Broadcom and the oils.

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Dollar Traders Believe What They See, Not What They Hear: Market Recon

Currency traders see the Trump administration boosting manufacturing via a weak dollar.

Jim's Daily Rundown

Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

AbbVie Becomes #133 Most Shorted S&P 500 Component, Replacing Equity Residential

AbbVie Becomes #133 Most Shorted S&P 500 Component, Replacing Equity Residential

The most recent short interest data has been released for the 12/29/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Deere & Co., Analog Devices, Mercadolibre, Teradyne, AbbVie, Antero Midstream Partners.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

A 'Bomb Cyclone' snowstorm could dump as much as 18 inches on New York and Boston Thursday, the National Weather Service has warned, as the Atlantic coast faces yet another extreme weather battering.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

TheStreet Quant Rating: B- (Buy)